NewLimit Raises $130M to Advance AI-Driven Anti-Aging Therapies

NewLimit, a biotechnology startup focused on extending human healthspan by genetically reprogramming cells, has secured $130 million in a Series B funding round led by venture capital firm Kleiner Perkins. The raise marks a significant milestone for the four-year-old company…